Citation & Authors
JAMA Netw Open. 2024;7(6):e2416578.
ABSTRACT · CHINESE TRANSLATION
Translated abstract
Translated from the licensed abstract via the Chinese version. This is not an official journal translation.
importance
Lupus nephritis is a major complication of systemic lupus erythematosus (SLE). Randomized clinical trials have shown kidney and cardiac protective effects of SGLT2 inhibitors.
purpose
To investigate whether SGLT2 inhibitor use is associated with the development or progression of lupus nephritis and other cardiorenal outcomes in patients with SLE and type 2 diabetes.
Design, site and participants
This multicenter cohort study used the US Collaborative Network of the TriNetX clinical data platform to identify patients with SLE and type 2 diabetes between January 1, 2015, and December 31, 2022. Data collection and analysis took place in September 2023.
exposed
Patients were divided into SGLT2 inhibitor users and nonusers and matched 1:1 using propensity scores.
Main outcomes and measures
Kaplan–Meier methods and Cox proportional hazards regression were used to calculate adjusted hazard ratios (AHRs) for lupus nephritis, dialysis, kidney transplantation, heart failure, and death within 5 years in the two groups.
result
Among 31,790 eligible patients, propensity score matching selected 1,775 pairs of users and nonusers, totaling 3,550 patients. After matching, the mean age was 56.8 years (SD 11.6), and 3,012 patients (84.8%) were women. Compared with nonusers, users had significantly lower risks of lupus nephritis (AHR 0.55; 95% CI 0.40–0.77), dialysis (0.29; 0.17–0.48), kidney transplantation (0.14; 0.03–0.62), heart failure (0.65; 0.53–0.78), and all-cause mortality (0.35; 0.26–0.47).
Conclusion and significance
In this cohort with SLE and type 2 diabetes, SGLT2 inhibitor users had significantly lower risks of lupus nephritis, dialysis, kidney transplantation, heart failure, and all-cause mortality, suggesting possible cardiorenal protection.
Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.
Original work license:CC BY ↗;Translations are subject to the same licensing conditions.
